Exelixis (EXEL) Accumulated Expenses (2010 - 2026)
Exelixis (EXEL) recorded quarterly Accumulated Expenses of $87.5 million in Q2 2026, down 14.39% quarter-over-quarter from $102.2 million in Q1 2026, and down 2.49% on a YoY basis from $89.7 million in Q2 2025.
Exelixis (EXEL) Accumulated Expenses (2010 - 2026) Analysis & Trends
Exelixis' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $87.5 million for Q2 2026.
- In Q2 2026, Accumulated Expenses fell 2.49% year-over-year to $87.5 million; the TTM figure through Apr 2026 stood at $87.5 million (down 2.49% YoY), while the FY2026 annual figure was $102.2 million, down 6.93% from the prior year.
- Accumulated Expenses was $87.5 million for Q2 2026 at Exelixis, down from $102.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $109.8 million in Q1 2025 to a low of $42.8 million in Q2 2022.
- Historically, Accumulated Expenses has averaged $79.4 million across 5 years, with a median of $77.2 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Accumulated Expenses soared 32.23% in 2023, then declined 6.93% in 2026.
- A 5-year view of Accumulated Expenses shows it stood at $77.2 million in 2022, then rose by 20.95% to $93.3 million in 2023, then fell by 2.91% to $90.6 million in 2024, then increased by 15.19% to $104.4 million in 2025, then dropped by 16.15% to $87.5 million in 2026.
- The last three Accumulated Expenses figures came in at $87.5 million (Q2 2026), $102.2 million (Q1 2026), and $104.4 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Exelixis | 13.72 Bn | 12.95 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 87.51 Mn |
| Jan 2, 2026 | 102.22 Mn |
| Oct 3, 2025 | 104.36 Mn |
| Jul 4, 2025 | 72.25 Mn |
| Apr 4, 2025 | 89.75 Mn |
| Jan 3, 2025 | 109.83 Mn |
| Sep 27, 2024 | 90.61 Mn |
| Jun 28, 2024 | 71.81 Mn |
| Mar 29, 2024 | 72.96 Mn |
| Dec 29, 2023 | 93.33 Mn |
| Sep 29, 2023 | 81.40 Mn |
| Jun 30, 2023 | 68.21 Mn |
| Mar 31, 2023 | 56.55 Mn |
| Dec 30, 2022 | 77.16 Mn |
| Sep 30, 2022 | 66.93 Mn |
| Jul 1, 2022 | 61.45 Mn |
| Apr 1, 2022 | 42.77 Mn |
| Dec 31, 2021 | 61.97 Mn |
| Oct 1, 2021 | 53.31 Mn |
| Jul 2, 2021 | 48.32 Mn |